Want to see AU:CMB full AI Analyst Report?
CMB Stock Chart & Stats
AU$0.47
-AU$0.02(-4.44%)
At close: 4:00 PM EST
AU$0.47
-AU$0.02(-4.44%)
Day’s Range― - ―
52-Week RangeAU$0.34 - AU$0.60
Previous CloseN/A
Volume21.69K
Average Volume (3M)5.25K
Market Cap
AU$11.48M
Enterprise ValueAU$9.96
Total Cash (Recent Filing)AU$1.12M
Total Debt (Recent Filing)AU$149.80K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding29,431,917
10 Day Avg. Volume9,372
30 Day Avg. Volume5,247
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)4.31
Price to Sales (P/S)15.99
P/FCF Ratio-3.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet RecoveryThe return to positive equity provides a stronger capital base than in 2023 and improves financial resilience. This supports continued development activity, although persistent losses could erode the improvement if profitability does not recover.
Lower LeverageDebt reduction lowers interest and refinancing pressure and gives the company greater flexibility while it develops regenerative medicine products. Moderate leverage is a relative strength, although it does not remove the need to fund ongoing operating losses.
Revenue ReboundThe return to recurring revenue after near-zero results in 2022–2023 indicates some commercial activity has resumed. A larger revenue base could support future scale, though the recovery remains modest and has not yet produced sustainable profitability.
Bears Say
Persistent Operating LossesMulti-year operating losses show that current products and activities have not yet reached an economically sustainable scale. Continued losses can consume capital, weaken the balance sheet and increase reliance on external funding for development.
Sustained Cash BurnPersistent negative cash generation limits the company’s ability to finance trials and commercialisation internally. Unless operating cash flow improves, Regeneus may need further capital, creating ongoing funding and potential dilution risk.
Unstable Revenue BaseHighly volatile and currently small revenue makes forecasting difficult and suggests commercial traction is not yet dependable. The 2026 decline after the rebound further indicates that revenue may not yet support the company’s development cost base.
Regeneus Ltd. News
CMB FAQ
What was Regeneus Ltd.’s price range in the past 12 months?
Regeneus Ltd. lowest share price was AU$0.34 and its highest was AU$0.60 in the past 12 months.
What is Regeneus Ltd.’s market cap?
Regeneus Ltd.’s market cap is AU$11.48M.
When is Regeneus Ltd.’s upcoming earnings report date?
Regeneus Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 182 days.
How were Regeneus Ltd.’s earnings last quarter?
Regeneus Ltd. released its earnings results on Aug 28, 2026. The company reported -AU$0.104 earnings per share for the quarter.
Is Regeneus Ltd. overvalued?
According to Wall Street analysts Regeneus Ltd.’s price is currently Overvalued.
Does Regeneus Ltd. pay dividends?
Regeneus Ltd. does not currently pay dividends.
What is Regeneus Ltd.’s EPS estimate?
Regeneus Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Regeneus Ltd. have?
Regeneus Ltd. has 29,431,917 shares outstanding.
What happened to Regeneus Ltd.’s price movement after its last earnings report?
Regeneus Ltd. reported an EPS of -AU$0.104 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Regeneus Ltd.?
Currently, no hedge funds are holding shares in AU:CMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Regeneus Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.02%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.21%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Regeneus Ltd.
Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Living Cell Technologies
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―